Ron Bentsur
Known title: Chairman & CEOCIK: 0001251213
Ron Bentsur's purchase track record
How the stock did after each of Ron Bentsur's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
31
of 32 since February 4, 2022
Stock higher 6 months later
55%
3 months: 44%
Median 6-month return
+10.9%
3 months: -9.9%
Beat the S&P 500
55%
median +14.4% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/30/2026 | NVCT | $250K | +11.6% | pending | — |
| 11/5/2025 | NVCT | $29K | +49.7% | +77.0% | +8.4% |
| 12/24/2024 | NVCT | $21K | +86.7% | +71.6% | +0.9% |
| 11/15/2024 | NVCT | $98K | +57.6% | +99.4% | +1.5% |
| 5/10/2024 | NVCT | $26K | +5.9% | +68.9% | +14.8% |
| 3/18/2024 | NVCT | $51K | -34.4% | -38.8% | +9.4% |
| 10/4/2023 | NVCT | $55K | -24.7% | -25.0% | +22.2% |
| 8/16/2023 | NVCT | $2K | -42.5% | -47.9% | +13.5% |
| 8/8/2023 | NVCT | $8K | -39.6% | -50.7% | +10.1% |
| 7/14/2023 | NVCT | $10K | -38.1% | -43.7% | +6.2% |
| 7/6/2023 | NVCT | $7K | -28.4% | -44.9% | +6.3% |
| 6/21/2023 | NVCT | $21K | -23.0% | -53.4% | +7.6% |
| 6/7/2023 | NVCT | $6K | -19.6% | -52.2% | +6.6% |
| 5/24/2023 | NVCT | $9K | -16.3% | -52.6% | +10.7% |
| 5/16/2023 | NVCT | $5K | -16.2% | -50.1% | +9.4% |
| 3/23/2023 | NVCT | $3K | +46.1% | +12.7% | +9.7% |
| 3/20/2023 | XAIR | $15K | -3.7% | -56.8% | +12.7% |
| 3/14/2023 | NVCT | $29K | +78.0% | +35.5% | +13.8% |
| 11/28/2022 | NVCT | $3K | +55.1% | +142.7% | +6.1% |
| 11/18/2022 | NVCT | $5K | +37.9% | +135.1% | +5.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Beyond Air Affirms FY2027 Sales Guidance at $16‑18M. Beyond Air Inc. (XAIR) confirmed its FY2027 sales guidance at $16‑18 million, matching the $16.715 million estimate from analysts. The company also reported preliminary Q2 revenue of about $2.3 million and reiterated the same FY2026 revenue range of $16‑18 million. These updates suggest the firm is on track to meet its projected sales targets for the next few years.
Transaction History
| NVCT | ▲ Buy | Open Market | 12,500 | $250K | 6/30/2026 | View on chart |
| NVCT | ▲ Buy | Grant | 150,000 | $0 | 1/6/2026 | View on chart |
| NVCT | ▲ Buy | Open Market | 5,000 | $29K | 11/5/2025 | View on chart |
| NVCT | ▲ Buy | Grant | 250,000 | $0 | 1/2/2025 | View on chart |
| NVCT | ▲ Buy | Open Market | 4,500 | $21K | 12/24/2024 | View on chart |
| NVCT | ▲ Buy | Open Market | 20,000 | $98K | 11/15/2024 | View on chart |
| NVCT | ▲ Buy | Open Market | 1,940 | $13K | 5/14/2024 | View on chart |
| NVCT | ▲ Buy | Open Market | 2,000 | $13K | 5/10/2024 | View on chart |
| NVCT | ▲ Buy | Open Market | 5,000 | $51K | 3/18/2024 | View on chart |
| NVCT | ▲ Buy | Open Market | 640 | $7K | 10/10/2023 | View on chart |
| NVCT | ▲ Buy | Open Market | 830 | $9K | 10/9/2023 | View on chart |
| NVCT | ▲ Buy | Open Market | 250 | $3K | 10/6/2023 | View on chart |
| NVCT | ▲ Buy | Open Market | 1,400 | $16K | 10/5/2023 | View on chart |
| NVCT | ▲ Buy | Open Market | 1,820 | $20K | 10/4/2023 | View on chart |
| NVCT | ▲ Buy | Open Market | 115 | $2K | 8/16/2023 | View on chart |
| NVCT | ▲ Buy | Open Market | 235 | $3K | 8/15/2023 | View on chart |
| NVCT | ▲ Buy | Open Market | 180 | $3K | 8/11/2023 | View on chart |
| NVCT | ▲ Buy | Open Market | 120 | $2K | 8/8/2023 | View on chart |
| NVCT | ▲ Buy | Open Market | 225 | $3K | 7/21/2023 | View on chart |
| NVCT | ▲ Buy | Open Market | 110 | $2K | 7/20/2023 | View on chart |
| NVCT | ▲ Buy | Open Market | 200 | $3K | 7/19/2023 | View on chart |
| NVCT | ▲ Buy | Open Market | 150 | $2K | 7/14/2023 | View on chart |
| NVCT | ▲ Buy | Open Market | 110 | $2K | 7/7/2023 | View on chart |
| NVCT | ▲ Buy | Open Market | 320 | $5K | 7/6/2023 | View on chart |
| NVCT | ▲ Buy | Open Market | 750 | $12K | 6/26/2023 | View on chart |
| NVCT | ▲ Buy | Open Market | 500 | $9K | 6/21/2023 | View on chart |
| NVCT | ▲ Buy | Open Market | 120 | $2K | 6/8/2023 | View on chart |
| NVCT | ▲ Buy | Open Market | 230 | $4K | 6/7/2023 | View on chart |
| NVCT | ▲ Buy | Open Market | 330 | $6K | 5/31/2023 | View on chart |
| NVCT | ▲ Buy | Open Market | 200 | $3K | 5/24/2023 | View on chart |
| NVCT | ▲ Buy | Open Market | 320 | $5K | 5/16/2023 | View on chart |
| NVCT | ▲ Buy | Open Market | 230 | $3K | 3/23/2023 | View on chart |
| NVCT | ▲ Buy | Open Market | 480 | $6K | 3/21/2023 | View on chart |
| XAIR | ▲ Buy | Open Market | 2,300 | $15K | 3/20/2023 | View on chart |
| NVCT | ▲ Buy | Open Market | 480 | $5K | 3/15/2023 | View on chart |
| NVCT | ▲ Buy | Open Market | 1,680 | $18K | 3/14/2023 | View on chart |
| NVCT | ▲ Buy | Grant | 210,000 | $0 | 1/12/2023 | View on chart |
| NVCT | ▲ Buy | Open Market | 150 | $1K | 11/30/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 150 | $1K | 11/29/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 150 | $1K | 11/28/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 150 | $1K | 11/25/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 500 | $4K | 11/18/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 250 | $2K | 11/17/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 1,000 | $7K | 11/10/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 500 | $4K | 9/30/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 500 | $4K | 9/28/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 500 | $4K | 9/26/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 1,000 | $8K | 9/23/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 1,200 | $10K | 9/2/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 500 | $4K | 9/1/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 1,000 | $9K | 8/29/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 500 | $5K | 8/23/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 5,000 | $45K | 8/19/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 14,426 | $124K | 8/18/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 19,669 | $165K | 8/11/2022 | View on chart |
| XAIR | ▼ Sell | Open Market | 40,000 | $261K | 6/30/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 3,700 | $43K | 6/29/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 300 | $4K | 6/28/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 400 | $5K | 6/24/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 200 | $2K | 6/23/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 100 | $1K | 6/22/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 500 | $8K | 5/27/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 500 | $8K | 5/26/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 1,000 | $16K | 5/20/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 200 | $4K | 5/19/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 700 | $14K | 5/18/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 1,000 | $18K | 5/18/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 200 | $4K | 5/17/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 110 | $2K | 5/17/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 1,000 | $19K | 5/16/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 700 | $13K | 5/13/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 1,100 | $16K | 5/12/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 600 | $10K | 5/12/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 10,545 | $182K | 5/12/2022 | View on chart |
| NVCT | ▲ Buy | Grant | 120,000 | $0 | 4/1/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 4,000 | $28K | 3/28/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 7,000 | $53K | 3/17/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 8,000 | $47K | 2/14/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 8,500 | $54K | 2/10/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 14,000 | $55K | 2/7/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 6,000 | $50K | 2/7/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 200,000 | $1.0M | 2/4/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 12,500 | $49K | 2/4/2022 | View on chart |
| XAIR | ▼ Sell | Open Market | 6,464 | $90K | 11/24/2021 | View on chart |
| XAIR | ▼ Sell | Open Market | 31,000 | $417K | 11/24/2021 | View on chart |
| XAIR | ▲ Buy | Option Exercise | 50,000 | $183K | 11/22/2021 | View on chart |
| XAIR | ▼ Sell | Tax Withholding | 12,536 | $183K | 11/22/2021 | View on chart |
| XTLB | ▲ Buy | Open Market | 15,279 | $20K | 8/21/2007 | View on chart |
| XTLB | ▲ Buy | Open Market | 1,600 | $5K | 8/25/2006 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Nuvectis Pharma to speak at Maxim Growth Summit 2026
Nuvectis Pharma announced it will participate in the Maxim Growth Summit 2026. This corporate event provides an opportunity for the company to share updates with investors and analysts. Such appearances are standard for public companies seeking to maintain visibility in the market.
Nuvectis Pharma to speak at Maxim Growth Summit 2026. Nuvectis Pharma announced it will participate in the Maxim Growth Summit 2026. This corporate event provides an opportunity for the company to share updates with investors and analysts. Such appearances are standard for public companies seeking to maintain visibility in the market.